Synchron Secures $200 Million to Advance Brain-Computer Interface
Photo by Bhautik Patel on Unsplash
Synchron secured $200 million to commercialize its Stentrode brain-computer interface, a less invasive technology designed to allow paralyzed individuals to control digital devices with their thoughts. The Stentrode, currently undergoing clinical trials in the U.S. and Australia with ten patients, aims to offer a safer alternative to open-brain surgery.
Key takeaways
- -based neurotechnology company, has secured $200 million in funding to accelerate the commercialization of its Stentrode brain-computer interface (BCI), according to Medtech Magazine
- The investment will facilitate bringing the Stentrode, a less-invasive technology, to market
- The Stentrode is designed to enable individuals with paralysis to control digital devices through thought
Related Topics
Want coverage like this for your company?
Local & industry wins build trusted proof, SEO/geo signals and prime national editors.
Verified mention available
Is this your company?
Set up real-time alerts and keep your Heartspace News coverage accurate. Verified teams can update profiles, request corrections, and collaborate on future stories.
Want to turn mentions into momentum? Find your best path with the Fit Checker. Verified profiles receive a free consult.